Business
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
The Phase III clinical trial, Flamingo-01, is now registered on clinicaltrials.gov with identifier NCT05232916 (view here), where more details about the
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":"\n\nThe Phase III clinical trial, Flamingo-01, is now registered on clinicaltrials.gov with identifier NCT05232916 (view here), where more details about the trial design and a preliminary listing of the initial clinical sites can be found\n\n\n\nCompany management will be attending the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held from April 8-13, 2022 in New Orleans, Louisiana\n\n\n\nA GP2 Phase III clinical trial poster will be presented in-person to provide updates on the Phase III clinical trial, Flamingo-01, and to continue the recruitment of clinical sites\n\n\n\nTwo additional posters will be presented in-person that cover additional findings from the Phase IIb clinical trial that we expect will lead to additional patent filings for the use of GLSI-100 in preventing recurring breast cancer\n\n\n\nWith the completion of three clinical lots of GP2 for use in the Flamingo-01 trial, and in any additional clinical trials run in parallel, the Company intends to file additional patent claims surrounding the manufacturing of GP2 and the administration of GLSI-100\n\n\n STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following:\n\nThe listing of the Flamingo-01 Phase III trial on clinicaltrials.gov provides clinicians and patients with an important source of information including trial updates and design, participating clinical sites, and contact information.\n\nThree abstracts/posters were accepted for presentation at the upcoming AACR Annual Meeting 2022. The AACR plans to publish the 3 abstracts on April 8, 2022 and the 3 posters on April 11-12, 2022.\n\nThe Company anticipates making various patent filings that cover clinical use of GLSI-100, use of immune response data to improve patient treatment, manufacturing of GP2, and the administration and preparation of GLSI-100. If these patent claims are issued, they have the potential to extend the patent life of GP2 beyond 2040.\n\nAbout the AACR Annual Meeting 2022\n\nThe AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer...